AIM
AIM ImmunoTech Inc.
$0.31
+0.01 (+1.83%)
At close · Jul 7
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”View the 10-Q filed May 15, 2026
Market Cap
$4.45M
Shares
14,563,515
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$88K
-48.2%
FY2025
Net Income
-$13.96M
+19.4%
FY2025
Gross Margin
-535.03%
+187.6pp
FY2014
Operating Margin
-13254.55%
-1624pp
FY2025
Diluted EPS
-$8.62
+72.1%
FY2025
Operating Cash Flow
-$10.96M
+26.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $94K | $88K | $170K | $202K | $141K | $135K | $163K | $140K | $367K | $437K | $92K | $133K | $197K | $150K | $213K | $161K | $135K | $111K | |
| $1.56M | — | — | — | — | — | — | — | — | — | — | — | $1.25M | $1.23M | $1.99M | $1.04M | $1.34M | $584K | |
| -$1.41M | — | — | — | — | — | — | — | — | — | — | — | -$1.05M | -$1.08M | -$1.78M | -$882K | -$1.21M | -$473K | |
| — | — | — | — | — | — | — | — | — | — | — | — | -535.03% | -722.67% | -833.8% | -547.83% | -893.33% | -426.13% | |
| $3.33M | $3.92M | $6.2M | $10.94M | $6.99M | $7.67M | $5.72M | $4.65M | $4.78M | $4.1M | $5.11M | $8.04M | $8.99M | $8.36M | $9.51M | $6.72M | $7.61M | $7M | |
| $6.92M | $7.7M | $13.71M | $21.14M | $13.07M | $8.67M | $8.65M | $7.04M | $6.2M | $6.57M | $7.68M | $7.15M | $9.06M | $7.72M | $9.06M | $6.69M | $7.57M | $5.8M | |
| — | $173K | $209K | $199K | $218K | $116K | $68K | $57K | $22K | $56K | $50K | $34K | $31K | $196K | — | — | — | — | |
| $10.37M | $11.75M | $19.94M | $32.12M | $20.06M | $18.97M | $15.32M | $12.58M | $11.86M | $11.85M | $13.9M | $16.78M | $19.3M | $17.32M | $20.55M | $14.46M | $16.52M | $13.38M | |
| -$10.27M | -$11.66M | -$19.77M | -$31.92M | -$19.92M | -$18.84M | -$15.15M | -$12.44M | -$11.5M | -$11.42M | -$13.8M | -$16.65M | -$19.1M | -$17.17M | -$20.34M | -$14.3M | -$16.39M | -$13.26M | |
| — | -13254.55% | -11630.59% | -15800% | -14129.79% | -13954.07% | -9295.71% | -8887.86% | -3132.43% | -2612.36% | -15004.35% | -12518.8% | -9694.92% | -11444.67% | -9549.3% | -8878.88% | -12138.52% | -11949.55% | |
| $992K | $812K | $585K | — | — | $67K | $672K | $427K | $201K | — | — | $3000 | $11K | $16K | $24K | $41K | $11K | $0 | |
| — | $3.18M | $5.19M | $1.07M | $629K | — | — | — | — | — | — | — | — | $775K | $1.57M | $583K | $2.37M | — | |
| -$11K | $17K | -$93K | $200K | -$1.68M | -$201K | $219K | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$13.96M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$13.28M | -$13.96M | -$17.32M | -$28.96M | -$19.45M | -$19.13M | -$14.4M | -$9.4M | -$9.83M | -$8.26M | -$7.5M | -$15.23M | -$17.45M | -$16.23M | -$17.35M | -$9.02M | -$13.14M | -$7.18M | |
| — | -15861.36% | -10188.24% | -14337.62% | -13790.78% | -14168.15% | -8834.36% | -6717.14% | -2677.66% | -1889.93% | -8154.35% | -11451.13% | -8857.87% | -10816.67% | -8147.42% | -5599.38% | -9730.37% | -6468.47% | |
| — | — | -$17.32M | -$28.96M | -$19.45M | -$19.08M | -$14.45M | -$9.4M | -$9.83M | -$8.24M | -$7.41M | -$15.17M | -$17.5M | -$16.3M | — | — | — | — | |
| USD/shares | — | -$8.62 | -$30.92 | -$58.20 | -$38.80 | -$38.80 | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$8.62 | -$30.92 | -$58.20 | -$38.80 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 1.62M | 560.17K | 500.92K | — | 488.08K | 328.3K | 37.56K | 10.35K | 295.65K | 224.95K | 202.89K | 161.77K | 1.73M | 1.45M | 1.4M | 1.38M | — |
| shares | — | 1.62M | 560.17K | 500.92K | 495.37K | 488.08K | 328.3K | 37.56K | 10.35K | 295.65K | 224.95K | 202.89K | 161.77K | 1.73M | 1.45M | 1.4M | 1.38M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Clinical Treatment Programs US | $141,000 | $135,000 | $144,000 |
| Clinical Treatment Programs Europe | — | — | $19,000 |